Blood Borders: State laws, vaccine misinformation, and the threat to the United States blood supply

Recent judicial decisions in Alabama and New York—one blocking the prosecution of individuals who assist with out-of-state reproductive healthcare,1 the other declining to enforce out-of-state civil judgments or criminal prosecutions related to the prescribing of abortifacients via telemedicine2—highlight a growing constitutional dilemma with wide-ranging implications: what are the legal and public health consequences when state-level restrictions contradict federal policy or the laws of other states? While these cases pertain to reproductive healthcare and differ in legal structure, they portend a broader, underrecognized crisis—namely, how state-level divergence in health regulation can disrupt nationally coordinated systems of care. Analogous legal and ideological conflicts are emerging in transfusion medicine, where state-level efforts to restrict the use of blood from donors vaccinated with mRNA-based COVID-19 vaccines threaten to fragment the blood supply and compromise its safety, availability, and scientific integrity (Figure 1). The United States (US) blood supply system is predicated on nationwide coordination, adherence to scientific standards, and a commitment to equitable access. Blood, by its nature, is not bound by state—or even national—borders.3 Licensed blood centers routinely transport units across regions to meet clinical demand, ensure equitable distribution, and respond to crises such as mass casualty events, natural disasters, cyberattacks, and regional shortages.4-7 Blood products may also be distributed internationally to support patients with rare blood types through rare donor programs.8, 9 This cross-jurisdictional movement underscores the inherently borderless nature of an effective blood supply system, which is essential for both routine operations and emergency response. The Food and Drug Administration (FDA), under authority from the Public Health Service Act and the Food, Drug, and Cosmetic Act, regulates the collection, processing, labeling, and distribution of blood.10, 11 Its jurisdiction is reinforced by the Supremacy Clause of the US Constitution, which refers to the foundational principle that, in general, federal law takes precedence over any conflicting state law, particularly in matters of interstate commerce.12 Blood, like other biologic products, is rigorously tested, tracked, and regulated. National safety standards have reduced the risk of transfusion-transmitted infections to negligible levels.13 This system's strength lies in its scientific integrity and coordinated infrastructure. However, this foundation is increasingly threatened by politicized efforts to regulate blood donation and transfusion practices at the state level—specifically related to COVID-19 vaccination. Since the introduction of COVID-19 vaccines, several state legislators have introduced bills that seek to restrict or dictate the use of blood products based on a donor's COVID-19 vaccination status.14-22 These efforts, though currently limited, are gaining political traction. Some proposals would require blood collection centers to label blood with the donor's COVID-19 vaccination status or prohibit donations from vaccinated individuals. Others seek to mandate that hospitals honor requests for “non-vaccinated blood” and impose penalties on providers who do not comply. None of these measures are supported by medical science.23, 24 Consistent with the broader scientific consensus, the FDA and major blood organizations—including the Association for the Advancement of Blood and Biotherapies (AABB), the American Red Cross, and America's Blood Centers—have affirmed that COVID-19 vaccination does not alter the safety, quality, or suitability of blood for transfusion.23-26 Rigorous studies confirm no clinical difference in patient transfusion outcomes based on donor vaccination status.23, 24 Nevertheless, misinformation has persisted,27 fueled by disinformation campaigns and pseudo-medical narratives surrounding “vaccine shedding,” “genetic contamination,” and blood “purity.”19 In 2022, a private clinic in Switzerland drew international attention for allegedly planning a separate blood bank for non-vaccinated donors.28 While no US laws have yet mandated such actions, similar ideologically motivated proposals have been introduced in multiple state legislatures.14-16, 20-22 That these bills are even being considered reveals how scientifically unsupported theories can nonetheless shape health policy. If enacted, state-level laws that restrict use or mandate labeling of blood based on donor vaccination status could directly conflict with existing FDA regulations. Legal precedent addressing interstate discrepancies in healthcare legislation suggests that such laws would not withstand judicial scrutiny. For example, Alabama's attempt to impose restrictions on reproductive healthcare was blocked on the grounds that it unconstitutionally interfered with interstate travel and commerce.29 Likewise, no state can unilaterally prohibit or limit the transportation of federally regulated biologics, including blood products, based on disagreement with national scientific standards and/or federal guidelines. Nevertheless, the aftermath of Dobbs v. Jackson Women's Health Organization—the 2022 Supreme Court decision that overturned Roe v. Wade and eliminated the federal Constitutional right to abortion, returning regulatory power to the states30—offers a cautionary tale of how disparate state-level laws can disrupt healthcare delivery. While the blood supply context differs—here, states are attempting to supersede an existing federal framework rather than fill a regulatory void—the downstream consequences may be similarly destabilizing. Following the Dobbs decision, numerous states enacted or revived statutes that, while not uniformly enforceable, generated widespread uncertainty.31, 32 Healthcare providers, unsure of what was legally permissible, faced increased liability exposure, while patients feared seeking services across borders,33, 34 culminating in delays and denials of care—even where state laws ultimately proved unconstitutional.35 In transfusion medicine, state efforts to impose vaccine-based restrictions on blood labeling, eligibility, or inventory could generate analogous uncertainty: blood centers unsure of compliance obligations, hospitals reluctant to accept cross-border units, and patients caught in a system where access to standard care varies by geography, whereby timely transfusion may be denied due to ideological constraints. Regardless of the legal architecture, when states pursue conflicting standards in domains requiring interstate coordination, the result is foreseeable: a fractured system that jeopardizes the timely, equitable, and safe delivery of care. Shield laws, such as those in New York, aim to protect healthcare providers from civil or criminal prosecution across state lines;36 however, their legal scope remains contested. A key area of uncertainty involves how these laws may be treated under the Full Faith and Credit Clause of the US Constitution, which generally obligates states to honor the judicial proceedings of other states.37 Historically, this has included enforcing judgments across states with differing criminal laws; for example, one state's judgment on a gambling debt can still be collected in another state where gambling is otherwise prohibited.38 Given Congress's Constitutional authority to regulate interstate travel and commerce, and to define when state-to-state legal variability is permissible or impermissible, Congress retains the power to preempt state-level restrictions on blood products or transfusion practices. Absent federal action, however, interstate legal conflicts—including those addressed by shield laws—may ultimately require adjudication by the US Supreme Court to clarify the scope of Full Faith and Credit, federal preemption, and interstate commerce authority.37-39 Yet with the US Supreme Court agreeing to hear only 1%–2% of the appeals (petitions for “certiorari”) submitted to it each year,40 many interstate legal conflicts—including those involving blood regulation—are unlikely to receive timely resolution. This low acceptance rate means that even critical issues may remain in legal limbo for years, perpetuating regulatory uncertainty and placing the blood supply at sustained risk. If a patchwork of state-level regulations governing transfusion practices emerges, the US blood supply could face unprecedented disruption. Requirements that only blood from non-vaccinated donors be used within a state, or that all units be labeled by donor vaccination status, would force blood centers and hospitals into complex legal, ethical, and operational dilemmas. Would a hospital in a restrictive state be required to refuse life-saving blood from a vaccinated donor routed across state lines? Would blood collection centers and hospitals need to segregate inventory and redesign systems based on ideology rather than medical science? If a directed donor crosses state borders to support a specific patient with a rare blood type, would that donation be subject to conflicting regulatory requirements? These are no longer theoretical concerns, but rather represent foreseeable outcomes of politicized, non-evidence-based policymaking. Such regulation threatens the coordinated infrastructure on which the safety and availability of the national blood supply depend. Mandating the segregation of blood inventories by donor COVID-19 vaccination status would require extensive overhauls across the entire blood supply chain, including new validation processes for storage, labeling, tracking, and distribution. Importantly, there is currently no FDA-approved assay capable of determining a donor's COVID-19 vaccination status or specific vaccine received. Therefore, labeling units in accordance with vaccination status is not feasible under current regulatory frameworks. Nonetheless, under such state-level mandates, blood centers and hospitals could be compelled to develop redundant information technology (IT) infrastructure and Blood Establishment Computer Systems (BECS), maintain segregated physical inventories, and retrain personnel—while simultaneously contending with persistent blood shortages.41-51 In addition to the regulatory considerations, labeling and storing blood by vaccination status introduces unnecessary complexity into clinical practice. It increases the risk of product selection errors, mis-transfusion, and workflow disruptions, ultimately compromising, rather than improving, transfusion safety.52, 53 Legal ambiguity surrounding such mandates may also lead to overly cautious or inconsistent interpretations of vague directives, further impeding the interstate sharing of blood products. If blood is no longer universally accepted across state lines, the US blood supply risks devolving into a patchwork of local or hyper-local systems, threatening timely and equitable access—particularly in regions with limited donor pools or higher clinical demand—and placing vulnerable patient populations at avoidable risk. Requiring disclosure of vaccination status may violate federal health privacy laws and established blood donor confidentiality standards,54-56 potentially exposing blood centers and healthcare providers to legal liability. Additionally, donors may be unaware of their entire vaccination history or unable to accurately recall the specific vaccine subtype(s) they received. Rather than consent to ideologically motivated tracking, donors may withdraw from the system entirely, further jeopardizing an already strained blood supply. Labeling blood products with vaccination status, or segregating or banning blood from vaccinated donors, may unintentionally validate misinformation, implying that vaccination status impacts blood quality or affects transfusion outcomes. If governments legitimize non-scientific concerns about blood safety, public confidence in that safety may erode. These policies might also influence patient requests, empowering individuals to reject safe, appropriately screened blood products because of misinformation and unfounded beliefs. This is particularly concerning for marginalized or vaccine-hesitant communities already subject to misinformation. Once lost, public trust is difficult to restore. Hospitals and healthcare providers face untenable choices: either honor a patient's request for non-vaccinated blood or adhere to evidence-based transfusion practices. These debates reflect broader tensions in medicine surrounding informed consent, the accommodation of patient preferences, and the limits of clinical discretion.25, 57, 58 Addressing them will require thoughtful, multidisciplinary dialogue among stakeholders across the blood supply chain. Ideologically motivated regulation of blood is not new. Transfusion medicine has historically been subject to intense ideological interference, including the segregation of blood by donor characteristics such as race—practices based not on clinical evidence, but in social prejudice and political bias.19, 59 This history underscores the risks of labeling or restricting blood products based on donors' personal, scientifically insignificant health attributes. Blood is a foundational component of the healthcare system, essential to a wide range of critical services, including emergency care, trauma resuscitation, surgery, obstetric delivery, and the management of cancer and chronic diseases. Even brief disruptions to the availability or distribution of blood can have severe and potentially fatal consequences. State-level attempts to regulate the blood supply due to misinformation or unsubstantiated claims must therefore be recognized not only as a public health threat but also as a fundamental risk to the integrity of the healthcare system. To mitigate this risk, there is an urgent need for a clear articulation of the legal authority and ethical imperatives that justify and support centralized federal oversight of the US blood system. Blood collection centers and healthcare providers are likely to be at the forefront of emerging jurisdictional and regulatory conflicts should states enact legislation requiring the segregation of blood products based on COVID-19 vaccination status or other unscientifically unsupported criteria. However, individual institutions and medical professionals will lack the authority to resolve conflicting state and federal mandates. Preserving the integrity of the national blood supply and ensuring evidence-based practice necessitate federal action. This includes legal, operational, and public health strategies that preserve scientific integrity, protect institutions and providers, and restore public confidence in a system designed to serve the entire population. First, the US Congress should formally designate the blood supply as critical infrastructure under the Homeland Security Act or through an amendment to the Public Health Service Act. This designation would not only elevate the national visibility of blood as an essential health system component, but also provide a legal basis for prioritizing resources, securing supply chains, enhancing emergency responsiveness, and insulating the system from local political disruption. Parallels can be drawn to systems like the United Network for Organ Sharing and the National Vaccine Program, which rely on centralized oversight at the national level to maintain equity and functionality. A critical infrastructure designation would enable the Department of Homeland Security (DHS), the Department of Health and Human Services (HHS), and the FDA to coordinate in securing and standardizing the blood system across state lines. Second, Congress should take immediate steps to clarify that federal law preempts any state legislation that attempts to regulate the collection, labeling, or distribution of blood in a way that contradicts FDA or national standards, such as those set by the AABB. This could include statutory language reaffirming that blood is a federally regulated biologic and that any labeling requirements must be dictated by FDA-licensed testing, not ideological or unscientific criteria. One model for such action is the FDA's existing authority to mandate uniform labeling practices and prohibit misleading or non-standard information on licensed biologics. Congress may also consider targeted amendments to the Public Health Service Act, similar to the way in which it delineates the federal role in vaccine safety and distribution. Third, healthcare institutions, blood centers, and healthcare providers acting in accordance with national—and international—transfusion standards should be legally protected from civil or criminal liability arising from conflicting state laws. Analogous to reproductive health shield laws recently invoked in states like New York and California, such protections should extend to refusals to label, segregate, or restrict blood products based on non-scientific criteria. These laws should explicitly address multiple areas, including: (1) jurisdictional immunity for providers participating in interstate blood transfer; (2) prohibitions against disclosing donor vaccination status without consent; and (3) legal defenses against retaliatory lawsuits based on adherence to national guidelines. These protections could reduce institutional hesitancy and provide legal clarity in situations where laws appear to conflict. We acknowledge that federal oversight, while often more coordinated, is not inherently immune to ideological influence. Recent history has shown that national policies—including those affecting public health—can be shaped by political agendas, delayed action, or disregard for scientific evidence.60-64 In such instances, states may serve as important counterweights by advancing science-based protections or addressing regulatory gaps. However, fragmented or contradictory state policies—especially those lacking evidence—pose unique risks to nationally integrated systems like the blood supply. Therefore, we advocate not simply for federal dominance, but for a multi-tiered system of governance anchored in scientific integrity, with clear mechanisms for accountability and corrective action whether at the federal or state level. Ideally, such policies would be guided by experts in transfusion medicine and blood donation via collaboration with organizations such as AABB. Formal statements from professional societies and accrediting organizations that oppose ideologically driven regulation of the blood supply and affirm the safety of blood from vaccinated donors are critical to protecting the blood supply. These statements should be updated regularly and include guidance for blood centers and hospitals navigating politically sensitive requests. These guidance documents should outline best practices for patient refusals or requests for directed donation from non-vaccinated clarify when it is and legally permissible to such and provide model language for institutional policies that with national standards and protect clinical These could be existing for blood or ethical of medical Additionally, a coordinated public could misinformation and preserve public The of the in with the and other blood could lead efforts to the public on the safety of the blood on its on health should be and affirm the role of vaccination in ensuring donor and without the safety of blood Blood centers and health systems should be with guidance to address patient concerns and misinformation from clinical the US could coordinate with organizations such as the of American and America's Blood to the system for enacted laws, and legal related to blood A of legal public health and transfusion medicine professionals could be with emerging and stakeholders on compliance This could be integrated into an or supported through a The blood supply must remain from ideologically non-evidence-based practices. a of public health the US blood donor and collection, testing, distribution, and on scientific and coordinated, cross-jurisdictional Its integrated nature it untenable for states to based on local political Recent in reproductive healthcare policy the broader risk of regulatory when states standards in nationally integrated While federal authority may ultimately supersede state-level that disrupt interstate systems, the regulatory and disrupt access to essential healthcare In an where ideology and misinformation are increasingly health it is to define the legal, ethical, and scientific that the blood supply. Blood safety must be in evidence-based practice and by national To ensure that blood remains a safe and universally must be to protect this system from the jurisdictional that has already other of The of transfusion practice across state is not a of operational it is a public health was supported in by the National and Blood The no role in the of the or the decision to for and support from and Health of the submitted is a on a US clinical and support from and of the submitted is the on a US clinical is on the scientific of and is a in a by